PRDM9 and leukemia: DOT1L has been proposed to be a central component of oncogenic transformation by KMT2A fusion proteins in certain leukemias14,42, and we found that the DOT1L histone methyltransferase was significantly more enriched at oncofusion protein targets in KOPN-8, 1° AML-3 and 1° MPAL-1 samples than in the other leukemias we profiled (Fig. 4b).